NCT04773522 is a Phase 1 clinical trial of Talquetamab in Multiple Myeloma, sponsored by Janssen Pharmaceutical K.K..

Who is sponsoring NCT04773522?

NCT04773522 is sponsored by Janssen Pharmaceutical K.K..

What drugs are being tested in NCT04773522?

Interventions in NCT04773522: Talquetamab.

What condition does NCT04773522 study?

NCT04773522 studies Multiple Myeloma.

Is NCT04773522 still recruiting?

NCT04773522 is currently completed. Last updated 1 October 2025.

Last reviewed 2025-10-01 · How we verify

NCT04773522

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Completed Phase 1 Last updated 1 October 2025

What this trial tests

Phase 1 trial testing Talquetamab in Multiple Myeloma in 15 participants. Completed in 4 September 2025.

Timeline

20 May 2021

Primary endpoint
14 October 2022

4 September 2025

Quick facts

Lead sponsor	Janssen Pharmaceutical K.K.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	20 May 2021
Primary completion	14 October 2022
Estimated completion	4 September 2025
Sites	6 locations across Japan

Drugs / interventions tested

Talquetamab (TALQUETAMAB) — full drug profile →

Conditions studied

Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

Janssen Pharmaceutical K.K. — full company profile →

Who can join

20 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
Wei J, Yang Y, Wang G, Liu M. · · 2022 · cited 127× · PMID 36389699 · DOI 10.3389/fimmu.2022.1035276
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
Raje N, Anderson K, Einsele H, Efebera Y, et al · · 2023 · cited 120× · PMID 37528088 · DOI 10.1038/s41408-023-00879-7
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
Kegyes D, Constantinescu C, Vrancken L, Rasche L, et al · · 2022 · cited 53× · PMID 35672793 · DOI 10.1186/s13045-022-01296-2
Multiple myeloma: signaling pathways and targeted therapy.
Lu Q, Yang D, Li H, Niu T, et al · · 2024 · cited 50× · PMID 38961036 · DOI 10.1186/s43556-024-00188-w
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.
Ho M, Xiao A, Yi D, Zanwar S, et al · · 2022 · cited 20× · PMID 36421358 · DOI 10.3390/curroncol29110705
Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma.
Ackley J, Ochoa MA, Ghoshal D, Roy K, et al · · 2021 · cited 18× · PMID 34638271 · DOI 10.3390/cancers13194787
Application of GPRC5D Targeting Therapy in Relapsed Refractory Multiple Myeloma.
Yan S, Ming X, Zheng R, Zhu X, et al · · 2025 · cited 3× · PMID 40095426 · DOI 10.1002/cam4.70764
[Research progress in targeting GPRC5D for the treatment of multiple myeloma].
An JY, Pan MM, Ouyang HY, Mi JQ. · · 2024 · cited 2× · PMID 39414618 · DOI 10.3760/cma.j.cn121090-20240322-00109

Verify or expand the search:

Other trials of Talquetamab

Trials testing the same drug.

NCT07499323 — Talquetamab in Patients With Refractory Generalized Myasthenia Gravis · NA · not yet recruiting
NCT07032714 — Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07093554 — Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patie · Phase 1 · recruiting
NCT06572605 — External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extr · Phase 1, PHASE2 · recruiting
NCT06348108 — Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting

Other recruiting trials for Multiple Myeloma

Currently open trials in the same condition.

NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting

Other Janssen Pharmaceutical K.K. trials

Trials by the same sponsor.

NCT06295692 — A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis · Phase 3 · active not recruiting
NCT05926583 — A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa · Phase 3 · active not recruiting
NCT05567185 — A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer · Phase 1 · active not recruiting
NCT05167825 — A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension · Phase 3 · completed
NCT05242432 — A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04773522 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Janssen Pharmaceutical K.K.
Last refreshed: 1 October 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04773522.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing